SCHEMBL6894418

SCHEMBL6894418

Cn1ccc(-c2cnn3c(N)cc(N4CCN5C(=O)NC(=O)C5C4)nc23)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.36
RAB9A P51151 7/20 0.36
KDM4E B2RXH2 6/20 0.36
MAPT P10636 6/20 0.36
MEN1 O00255 5/20 0.36
KMT2A Q03164 5/20 0.36
HPGD P15428 5/20 0.36
ALDH1A1 P00352 4/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
HSD17B10 Q99714 4/20 0.36
TP53 P04637 2/20 0.36
MAPK1 P28482 2/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
GFER P55789 1/20 0.36
NPSR1 Q6W5P4 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7875490 0.88 CHEK1 (0.46) CHEK1CCNA2CDK2CCNA1NTRK1
SCHEMBL6893486 0.83 CHEK1 (0.40) CHEK1CCNA2CDK2CCNA1BMPR1A
SCHEMBL6894420 0.81 PIK3CA (0.36) NPC1RAB9AKDM4EMAPTMEN1
SCHEMBL6891847 0.79 CHEK1 (0.46) NPC1RAB9AKDM4EMAPTMEN1
SCHEMBL6891842 0.75 CRBN (0.41) NPC1RAB9AKDM4EMAPTMEN1
SCHEMBL7882268 0.73 CHEK1 (0.52) CHEK1CCNA2CDK2CCNA1PIM1
SCHEMBL10239462 0.73 KDM4E (0.37) NPC1RAB9AKDM4EMAPTMEN1
SCHEMBL6894425 0.71 CHEK1 (0.50) CHEK1CCNA2CDK2CCNA1PIM1
SCHEMBL7885236 0.69 PIK3CA (0.36)
SCHEMBL6893405 0.67 EGFR (0.35) CHEK1CCNA2CDK2CCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS BACE1, BACE2, PSEN1 NPC1 1172/4885RAB9A 2744/4885KDM4E 3091/4885
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MTOR, RICTOR, RPTOR NPC1 348/4885RAB9A 720/4885KDM4E 1448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.